EHMSG 2020 Virtual Conference | e-Poster Presentations

Electronic Poster Round 1: Diagnosis of Helicobacter infection

 

EP1.01
“Test-and-Treat” strategy with urea breath test: a cost-effective approach for the management of Helicobacter pylori-related dyspepsia and the prevention of peptic ulcer in the United Kingdom-Results of the Hp-Breath initiative
David PRITCHARD, Liverpool, United Kingdom

EP1.02
Comparative estimation of results of the new selective rapid urease test and detection of H. pylori in stool: a pilot study
Natalia Baryshnikova, St-Petersburg, Russian Federation

EP1.03
Screening for Helicobacter pylori infection and Clarithromycin resistance using real-time polymerase chain reaction
Mila Kovacheva-Slavova, Sofia, Bulgaria

EP1.04
Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding- The results of a network meta-analysis
Nóra Vörhendi, Pécs, Hungary

EP1.05
Helicobacter pylori screening in patients with acute myocardial infarction
Robin Hofmann, Stockholm, Sweden

EP1.06
Diagnosis of Helicobacter pylori infection in the elderly by immunochromatographic assay-based stool antigen test
Yingjie Han, Beijing, China

EP1.07
Implementation of the program of the Scientific Society of Gastroenterologists of Russia "Physicians without helicobacteriosis" in Chita
Elena Luzina, Chita, Russian Federation

EP1.08
'Helicobacter pylori and mast cells in the mucous membrane of the stomach'
Natalya Samodurova, Voronezh, Russian Federation

EP1.09
'Immunomorphological aspects of evaluating the interaction of mast cells and Helicobacter pylori in the stomach muсous'
Natalya Samodurova, Voronezh, Russian Federation

 


Electronic Poster Round 2: Treatment of Helicobacter infection

EP2.01
Quality assessment of meta-analyses: probiotics and eradication of Helicobacter pylori infection
György Buzás, Budapest, Hungary

EP2.02
Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: a systematic review and meta-analysis
Doron Boltin, Petah Tikva, Israel

EP2.03
European registry on Helicobacter pylori management (Hp-EuReg): first-line therapy in Israel
Doron Boltin, Petah Tikva, Israel

EP2.04
Eradication rate of Helicobacter pylori infection in Chinese duodenal ulcer patients treated with Vonoprazan 20 mg versus Lansoprazole 30mg with bismuth containing quadruple therapy
Jiangbin Wang, Changchun, China

EP2.05
Helicobacter pylori eradication first- and second-line regimens prescriptions and effectiveness in Lithuania: Analysis From the European Registry on H. pylori Management (Hp-EuReg)
Laimas Jonaitis, Kaunas, Lithuania

EP2.06
Helicobacter pylori eradication treatment in Lithuania during 2013-2019: trend analysis of the European Registry on H. pylori management (Hp-EuReg)
Paulius Jonaitis, KAUNAS, Lithuania

EP2.07
Difference in the Helicobacter pylori eradication rates according to the time of treatment start in patients with peptic ulcer bleeding
Hak Kim, Seoul, Korea, Republic of

EP2.08
Current trend in the Helicobacter pylori eradication rates of first-line sequential and concomitant therapies in Korea: A nationwide multicenter retrospective study over the 10 years
Byung-Wook Kim, Incheon, Korea, Republic of

EP2.09
Comparing efficacy of Helicobacter pylori eradication regimens: Bismuth containing quintet therapy vs. moxifloxacin based sequential therapy as first-line eradication regimen
Yoo Jin Kim, Bundang, Korea, Republic of

EP2.10
First-line H. pylori eradication therapy in Europe: Results from 24,882 cases of the European Registry on H. pylori Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.11
Room for improvement in the treatment of Helicobacter pylori infection: lessons from the European Registry on H. pylori Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.12
European Registry on H. pylori Management (Hp-EuReg): empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2020
Javier Gisbert, Madrid, Spain

EP2.13
European Registry on H. pylori Management (Hp-EuReg): Analysis of empirical second-line treatments in Europe
Javier Gisbert, Madrid, Spain

EP2.14
A deadly hug: chitosan microspheres functionalized with MSI-78A antimicrobial peptide kill Helicobacter pylori
Diana Fonseca, Universidade do Porto, Portugal

EP2.15
Bismuth quadruple three-in-one single capsule: 3 or 4 times daily? Sub-analysis of the Spanish data of the European Registry on H. pylori Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.16
European Registry on H. pylori Management (Hp-EuReg): Experience with single capsule bismuth quadruple therapy in 3,439 patients
Javier Gisbert, Madrid, Spain

EP2.17
Safety of the treatment of H. pylori infection: experience from the European Registry on H. pylori Management (Hp-EuReg) on 22,000 patients.
Javier Gisbert, Madrid, Spain

EP2.18
Bismuth quadruple regimen with tetracycline or doxycycline versus Pylera® as third-line rescue therapy for H. pylori infection: A prospective multicenter analysis of the European Registry on Helicobacter pylori Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.19
European Registry on H. pylori Management (Hp-EuReg): Clinical phenotypes through machine learning of first-line treated patients in Spain during the period 2013-2018
Javier Gisbert, Madrid, Spain

EP2.20
Empirical versus susceptibility-guided treatment of Helicobacter pylori infection: a meta-analysis
Javier Gisbert, Madrid, Spain

EP2.21
Real-world comparative effects of three-in-one single capsule bismuth quadruple therapy vs. non-bismuth quadruple concomitant therapy: Interim analysis of the European Registry on H. pylori Management (Hp-EuReg)
Ignasi Puig, Madrid, Spain

EP2.22
Antibiotic resistance trends of Helicobacter pylori naïve patients in the period 2013-2019: analysis of the European Registry on H. pylori Management (Hp-Eu-Reg)
Luis Bujanda Fernandez de Pierola
, Madrid, Spain

EP2.23
Tailored therapy based on clarithromycin resistance is effective for the first-line therapy of Helicobacter pylori
Sang Gon Moon, Seoul, Korea, Republic of

EP2.24
Helicobacter pylori antibiotic resistance: data from the European Registry on H. pylori Management (Hp-EuReg)
Luis Bujanda Fernandez de Pierola, Madrid, Spain

EP2.25
Impact of Helicobacter pylori clarithromycin resistance on the treatment effectiveness: data of the European Registry on H. pylori Management (Hp-EuReg)
Luis Bujanda Fernandez de Pierola
, Madrid, Spain

EP2.26
Trends in the effectiveness of eradication therapy in Russia
Dmitry Bordin, Moscow, Russian Federation


EP2.27
The comparison of side effects and effectiveness of standard triple therapy with clarithromycin and alternative high-dose amoxicillin / bismuth therapy in eradication of H.pylori
Alise Lielause, Riga, Latvia

EP2.28
The effects of Eupatilin of NSAID-gastropathy associated with H. pylori
Igor Skrypnyk, Poltava, Ukraine

EP2.29
Excellent performance of 2-weeks tailored triple therapy in H. pylori infected children: Interim results of the new EuroPedHp Registry
Thu Giang Le Thi, Munich, Germany

EP2.30
Myricetin as a natural compound sensitizing H. pylori to antibiotics
Paweł Krzyżek, Wrocław, Poland

EP2.31
Counteracting Helicobacter pylori using drug-free nanostructured lipid carriers (NLC)
Rute Chitas, Porto, Portugal

EP2.32
Effectiveness of first-line H. pylori eradication therapy according to the daily statin-use: analysis of the European Registry on H. pylori Management (Hp-EuReg)
Maria Caldas, Madrid, Spain

EP2.33
Effectiveness of first-line H. pylori eradication treatments in Spain: results from the European Registry on H. pylori management (Hp-EuReg)
Maria Caldas, Madrid, Spain

EP2.34
Effectiveness of second-line H. pylori eradication treatments in Spain: results from the European Registry on H. pylori management (Hp-EuReg)
Maria Caldas, Madrid, Spain

EP2.35
Population study on the prevalence and antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium.
Alexander Vanden Bulcke, Leuven, Belgium

EP2.36
European registry on H. pylori management (Hp-EuReg): analysis of 1,782 empirical rescue therapies on third and subsequent lines
Diego Burgos-Santamaría, Madrid, Spain

EP2.37
Autoprobiotics in treatment of Helicobacter pylori gastritis
Elena Ermolenko, Saint-Petersburg, Russian Federation

EP2.38
Antibiotics susceptibility testing increases Helicobacter pylori eradication rates in dyspeptic patients from Egypt: a randomized controlled trial
Mohamed Alboraie, Darrasah, Egypt

EP2.39
Nifuratel in the eradication of Helicobacter pylori i
nfection in adults: results of a randomized comparative clinical trial
Natalia Dekhnich, Smolensk, Russian Federation

EP2.40
Toxic effects of bismuth on Helicobacter pylori associated with the intra-gastric acidity: a transmission electron microscopy study
Yi-Chia Lee, Taipei, Taiwan

EP2.41
A real-life study assessing the efficacy of single capsule Bismuth quadruple therapy supplemented with probiotics for H pylori eradication in patients naïve to treatment in a high clarithromycin resistance area
K. Priadko, Naples, Italy

EP2.42
Modified bismuth quadruple therapy with low dose metronidazole as first-line therapy for Helicobacter pylori infection
Gyu Young Pih, Seoul, Korea, Republic of

EP2.43
Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community
Robin Bruyndonckx, Antwerp, Belgium

EP2.44
Antibiotic Resistance Breakers to counteract the multidrug-resistance in Helicobacter pylori
Silvia Di Lodovico, Chieti, Italy

EP2.45
The effectiveness of various anti Helicobacter therapy regimens in Ukraine
Yana Nikiforova, Kharkiv, Ukraine

EP2.46
Potential role of new Resveratrol derivatives for the management of drug resistant Helicobacter pylori infection
Mara Di Giulio, CHIETI, Italy

EP2.47
Evaluation of antimicrobial activity against Helicobacter pylori and phytochemical analysis of extracts from Passiflora and Ilex species
Johan Castañeda, Bogota, Colombia

EP2.48
Empiric versus Clarithromycin-Resistance-Guided Therapy for Helicobacter pylori based on Polymerase Chain Reaction Results in Patients with Gastric Neoplasms or Gastric MALT Lymphoma: a Randomized Controlled Trial
Jue Lie Kim, Seoul, Korea, Republic of

EP2.49
Antioxidant and anti-inflammatory properties of a grape seed extracts against Helicobacter pylori infection
Teresa Alarcón, Madrid, Spain

EP2.50
Effects of temperature on the growth and metronidazole resistance in Helicobacter pylori
Meiliang Gong, Beijing, China

EP2.51
Amoxicillin secretion by gastric mucosa in patients with atrophic and nonatrophic gastritis undergoing H. pylori eradication therapy
Anastasiya Sablina, Saint-Petersburg, Russian Federation

EP2.52
The chimeric protein CTB-multiHp: immunological features and the ability to inhibit Helicobacter pylori activities.
Beatriz Meza, La Paz, Mexico

 


Electronic Poster Round 3: Gastric cancer

 

EP3.01
Application of gold nanoparticles and metal oxide sensors for non-invasive detection of gastric cancer
Linda Mezmale, Riga, Latvia

EP3.02
Identification of volatile organic compounds emitted by gastric juice
Linda Mezmale, Riga, Latvia

EP3.03
Helicobacter pylori CagA hijacks cortactin to control host cell migration via Vav2-mediated small GTPase Rac1 activation
Steffen Backert, Erlangen, Germany

EP3.04
The repeat regions of Helicobacter pylori VirB10-ortholog CagY can bind and activate toll-like receptor 5
Steffen Backert, Erlangen, Germany

EP3.05
Overexpression of toll-like receptor 5 in H. pylori-infected patients with or without neoplasia
Steffen Backert, Erlangen, Germany

EP3.06
H. pylori chronic gastritis: OLGA and OLGIM evaluation and serum biomarkers for risk assessment of gastric cancer development in Brazilian patients
Luiz Coelho, BELO HORIZONTE, Brazil

EP3.07
Evaluation of the nonspecific immunity in patients with gastric cancer with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.08
The role of non-specific monocytic phagocytes in the progression of gastric cancer associated with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.09
Features of lipid peroxidation and antioxidant protection in gastric cancer associated with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.10
Peculiarities of glutathione antioxidant protection functioning in gastric cancer associated with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.11
Trends in gastric cancer in the Alaska Native population, 1988-2017Trends in Gastric Cancer in the Alaska Native Population, 1988-2017
Leisha Nolen, Anchorage, United States

EP3.12
Gastric cancer risk factors due to life style
Elizaveta Ageeva, Simferopol, Russian Federation

EP3.13
Diffuse type gastric cancer is associated with high titer of anti-Helicobacter pylori antibody
Joo Hyun Lim, Seoul, Korea, Republic of

EP3.14
Aberrant MUC13 expression as prognostic marker for gastric cancer
Baptiste Oosterlinck, Antwerp, Belgium

EP3.15
Cost-effectiveness of Helicobacter pylori screening and eradication to prevent stomach cancer in Spain
Teresa Alarcón, Madrid, Spain

EP3.16
In vitro profiling of volotile organic compounds released and consumed by CLS-145 and HGC-27 gastric cell lines
Linda Mezmale, Riga, Latvia

EP3.17
Circulating tumor cells and TWIST expression in patients with metastatic gastric cancer
Gwang Ha Kim, Busan, Korea, Republic of

EP3.18
Endoscopic biopsy sampling during gastroscopy - discrepancies across Europe
Jan Bornschein, Oxford, United Kingdom

EP3.19
Impact of Helicobacter pylori infection and its virulence factor CagA on DNA damage repair machinery
Eleftherios Kontizas, Athens, Greece

EP3.20
The role of lactate in gastric carcinogenesis
Karla Vinasco-Pacheco, Sydney, Australia

EP3.21
ER stress and inflammation via autophagy influence Helicobacter pylori-related gastric cancer
Isidora Simovic, Sydney, Australia

EP3.22
Leukaemia Inhibitory Factor signalling for targeting cancer stem cells in gastric adenocarcinoma
Lornella Seeneevassen, Bordeaux, France

EP3.23
Cell-free DNA somatic alterations in plasma of gastric cancer patients: mutational spectra, association with tumor size and survival
Greta Streleckiene, Kaunas, Lithuania

EP3.24
Induction of precancerous phenotype of normal gastric epithelial cells after their long-term incubation with supernatant from Helicobacter pylori-infected cancer-associated fibroblasts in vitro. Involvement of transforming growth factor beta and its recep
Tomasz Brzozowski, Cracow, Poland

EP3.25
Microbial abundance of H. pylori assessed by high-throughput sequencing and prognosis of gastric cancer patients
Alexander Link, Magdeburg, Germany

EP3.26
Helicobacter pylori and Epstein-Barr virus co-infection in Greek patients with gastric malignancies
Beatriz Martinez-Gonzalez, Athens, Greece


EP3.27
Increasing Trend and Characteristics of Cardiac Cancer
Younghee Choe, Seoul, Korea, Republic of

 


Electronic Poster Round 4: Helicobacter infection - pathogenesis and host response

 

EP4.01
Important role of integrin receptors in controlling the AGS cell elongation/hummingbird phenotype by Helicobacter pylori CagA
Steffen Backert, Erlangen, Germany

EP4.02
The actin-binding protein cortactin is required for efficient AGS cell elongation by H. pylori CagA, but not for vacuolization and apoptosis by VacA
Steffen Backert, Erlangen, Germany

EP4.03
Type IV secretion of Helicobacter pylori CagA and ADP-heptose into oral epithelial cell lines
Steffen Backert, Erlangen, Germany

EP4.04
The role of pro-inflammatory and anti-inflammatory cytokines in the development of chronic atrophic gastritis with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.05
Immunoglobulins in chronic gastritis and chronic atrophic gastritis with H. pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.06
Features of the functioning of monocytes in chronic gastritis associated with Helicobacter pylori- infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.07
Role of monocytes during chronic atrophic gastritis associated with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.08
Features of lipid peroxidation and antioxidant protection in chronic atrophic gastritis associated with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.09
The role of the glutathione part of antioxidant protection in the development of atrophy in chronic gastritis associated with Helicobacter pylori infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.10
Indicators of proliferation and apoptosis of gastric epithelial cells in the indigenous inhabitants of the Republic of Tyva with Helicobacter pylori-positive duodenal ulcer
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

EP4.11
Immunophenotype of cell infiltrate of the gastric mucosa lamina propria in indigenous inhabitants of Khakassia with Helicobacter pylori-positive duodenal ulcer
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

EP4.12
Upregulation of intercellular cell adhesion molecule-1 in endothelial cells exposed to Helicobacter pylori outer membrane vesicles
JUNG MOGG KIM, Seoul, Korea, Republic of

EP4.13
Helicobacter pylori infection affects nitric oxide system in patients with chronic antral gastritis and diabetes mellitus type 2
Igor Skrypnyk, Poltava, Ukraine

EP4.14
ACTIVE FORMS OF OXYGEN IN MONOCYTE CULTURE UNDER HIGH DISSEMINATION WITH HELICOBACTER PYLORI
Irina Litvinova, Krasnoyarsk, Russian Federation

EP4.15
Helicobacter pylori alters expression of Notch pathway components in gastric epithelial cells and macrophages in a cell type-specific manner.
Rebecca FitzGerald, Dublin, Ireland

EP4.16
Presence of Matrix Metalloproteinase-9-positive Neutrophil Extracellular Traps (NETs) in gastric biopsies of H. pylori infected patients
Elissavet Michailou, Athens, Greece

EP4.17
Virulence gene cagA of Helicobacter pylori and severe esogastroduodenal diseases: is there a relationship?
Mônica Barbosa, Goiânia, Brazil

EP4.18
Clinical Treatment Outcomes and Prognosis of Gastric MALToma : A Single Center Experience
Won Shik Kim, Seoul, Korea, Republic of

EP4.19
Helicobacter pylori dupA virulence gene: risk factor or protector of gastropathies?
Mônica Barbosa, Goiânia, Brazil

EP4.20
Contribution of Helicobacter pylori to foam cell formation in experimental atherosclerosis
Agnieszka Krupa, Lodz, Poland

EP4.21
Modulation of Nrf2-mediated antioxidant response after infection with Helicobacter pylori may contribute to gastric cancer
Océane MARTIN, Bordeaux, France

EP4.22
Modulation of Helicobacter pylori adhesion to gastric epithelial cells by BCGOnko vaccine mycobacteria
Weronika Gonciarz, Lodz, Poland

EP4.23
Induction of autoantibodies in response to infection with CagA-positive Helicobacter pylori
Weronika Gonciarz, Lodz, Poland

 


Electronic Poster Round 5: Epidemiology

EP5.01
Prevalence and genetic features of drug resistant Helicobacter pylori strains from Zhengzhou
Chuan Liu, zhengzhou, China

EP5.02
Prevalence of Helicobacter pylori infection in north-eastern Romania- data from a tertiary care center
Elena Popovici, Iasi, Romania

EP5.03
Changes in the prevalence of Helicobacter pylori over last 25 years among Lithuanian medical students
Laimas Jonaitis, KAUNAS, Lithuania

EP5.04
Evaluation of dyspeptic symptoms in Helicobacter pylori-positive and negative students of Lithuanian University of Health Sciences
Laimas Jonaitis, Kaunas, Lithuania

EP5.05
The prevalence of CagA Helicobacter pylori in children of the Mongoloid population of Siberia
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP5.06
The influence of parental education on the prevalence of Helicobacter pylori in rural children
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP5.07
Trends in the prevalence of Helicobacter pylori in Russia
Dmitry Bordin, Moscow, Russian Federation

EP5.08
Time trends in acute upper gastrointestinal bleeding in Serbian adult population
Vladimir Milivojevic, Belgrade, Serbia

EP5.09
Relationship of Helicobacter pylori infection to lifestyle, sociodemographic and economic profile in dyspeptic patients
Mônica Barbosa, Goiânia, Brazil

EP5.10
Retrospective analysis of the H. pylori eradication rates in Crimean population.
Valeriy Kryvy, Simferopol, Russian Federation

EP5.11
Helicobacter pylori reinfection rates in Crimean population: follow-up study
Valeriy Kryvy, Simferopol, Russian Federation

 


Electronic Poster Round 6: Microbiology and genomics of Helicobacter

EP6.01
Changes in the fluoroquinolone resistance of Helicobacter pylori over a 14-year period and discovery of a novel mutation in DNA gyrase: a single center study in Korea
Jae Kim, Seoul, Korea, Republic of

EP6.02
Clarithromycin resistance of Helicobacter pylori strains isolated in St. Petersburg, Russia
Alena Svarval, Saint Petersburg, Russian Federation


EP6.03
The genomic polymorphism of clinical strains of H. pylori isolated in St. Petersburg, Russia.
Alena Svarval, Saint Petersburg, Russian Federation

EP6.04
Helicobacter pylori resistance, treatment outcome and point mutation analysis based on molecular testing in Serbian adult population
Vladimir Milivojevic, Belgrade, Serbia

EP6.05
Clarithromycin resistance is more common among less virulent Helicobacter pylori strains - Data from an Irish centre.
Rebecca FitzGerald, Dublin, Ireland

EP6.06
Pathway of focal adhesion and its relevant circRNAs and lncRNAs are involved with perianal Crohn's disease.
Shi-xue Dai, Guangzhou, China

EP6.07
Comparison in vitro of activity of various macrolides against Helicobacter pylori
Natalia Dekhnich, Smolensk, Russian Federation

EP6.08
East-Asian Helicobacter pylori strains synthesize heptan-deficient lipopolysaccharide
Hong Li, Chengdu, China

EP6.09
The role of two PDZ domains in HtrA from Helicobacter pylori in the protein quality control system
Urszula Zarzecka, Gdansk, Poland

EP6.10
New Helicobacter pylori prophage phylogenetic population from Colombian strains
Angela Muñoz, Bogotá, Colombia

EP6.11
Frequency of Helicobacter pylori cagA, dupA and vacA genotypes and their association with severity of gastric pathologies in clinical patients in midwestern Brazil
Mônica Barbosa, Goiânia, Brazil

EP6.12
Comparative genomic analysis of novel Helicobacter pylori strains isolated from domestic cats with gastritis reveals unique genetic profile that may contribute to colonization and pathogenicity in feline hosts
Anthony Mannion, Cambridge, United States

EP6.13
Current worldwide population structure of Helicobacter pylori
Roberto Torres, Shanghai, China

EP6.14
Muller’s ratchet-like effect in Helicobacter pylori, a highly recombining bacterial species.
Elise Tourrette, Shanghai, China

EP6.15
Characterization of Helicobacter pylori Infection in the upper gastrointestinal tract of Twins.
Alexander Link, Magdeburg, Germany

 


Electronic Poster Round 7: Helicobacter and extragastroduodenal disease

EP7.01
A potential association between Helicobacter pylori infection and metabolic syndrome-related nonalcoholic fatty liver disease severity
Jannis Kountouras, Thessaloniki, Macedonia, Greece

EP7.02
Impact of Helicobacter pylori eradication on the risk of incident nonalcoholic fatty liver disease
Hyuk Lee, Seoul, Korea, Republic of

EP7.03
Cohort study of Helicobacter pylori infection and the risk of Incident osteoporosis in women
Hyuk Lee, Seoul, Korea, Republic of

EP7.04
The prevalence of Helicobacter pylori and the structure of the gastric mucosa in elderly patients with GERD
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

EP7.05
Clinical implication of Helicobacter pylori infection for eosinophilic esophagitis : A single center experience
Eun Ji Lee, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of

EP7.06
The features of Helicobacter pylori infection and gastrointestinal manifestations of allergy in children of Eastern Siberia
Anna Barilo, Krasnoyarsk, Russian Federation

EP7.07
H. pylori prevalence in individuals with allergic disease in the Latvian population
Jelizaveta Aleksejeva, Riga, Latvia

EP7.09
Strain specific pathological changes in the liver of mice infected with Helicobacter pylori (H. pylori).
Sadia Khalid, tallinn, Estonia

EP7.10
Helicobacter pylory-induced inflammatory response mediates invadosome formation and emergence of hybrid epithelial/mesenchymal phenotype in infected hepatocytes
Olga Smirnova, Tallinn, Estonia

EP7.11
Role of Helicobacters in Idiopathic Parkinsonism: a systematic review
Rosalind Tucker, London, United Kingdom

EP7.12
H. pylori Associated to Irritable Bowel Syndrome (IBS)
Adriana Barrios, Quetzaltenango, Guatemala

 


Electronic Poster Round 8: Paediatric conditions

EP8.01
The peculiarities of stomach mucosa in Helicobacter pylori schoolchildren
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.02
Cytokines in Helicobacter pylori-associated gastritis in children with a family predisposition to gastric pathology
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.03
Cytokeratins CK20, CK7 in assessing the severity of lesions of the gastric mucosa in schoolchildren with Helicobacter pylori-associated gastritis
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.04
Levels of IL-2, IL-4 with erosive and ulcerative lesions of the gastroduodenal zone associated with Helicobacter pylori in schoolchildren with pathology of the digestive tract in parents
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.05
Is CDX2 in children an immunohistochemical marker for the adverse course of gastritis?
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.06
The relationship of blood leptin with Helicobacter pylori in children
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.07
Chronic Helicobacter Pylori infection in Siberian adolescents with gastroesophageal reflux disease (GERD)
Sergey Tereshchenko, Krasnoyarsk, Russian Federation

EP8.08
Efficacy of standard triple therapy in the eradication of Helicobacter pylori in Siberian children: a single centre experience of treatment outcomes
Sergey Tereshchenko, Krasnoyarsk, Russian Federation

EP8.09
Effect of Helicobacter pylori on the formation of erosive-ulcerative lesions of the gastroduodenal zone, GERD and their associative relationship
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP8.10
Application of liquid probiotic concentrate for gastroduodenitis of Helicobacter etiology in children
Olga Obukhova, Novosibirsk, Russian Federation

EP8.11
H. pylori infection in symptomatic Mexican children
Omaha Celestino-Perez, Mexico City, Mexico

 


Electronic Poster Round 9: Upper GI microbiota in health and disease

EP9.01
Treatment of non-erosive reflux disease and change of esophageal microbiome: A prospective multicenter study
Sang Kil Lee, Seoul, Korea, Republic of

EP9.02
Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: A prospective multicenter study
Chan Hyuk Park, Guri, Korea, Republic of

EP9.03
Helicobacter pylori and the possible probiotic Lactobacillus salivarius co-exist in Estonian gastric biopsy sample
Kaisa Roots, Tallinn, Estonia

 


Electronic Poster Round 10: Gut microbiota and non-intestinal disease

EP10.01
Effect of fecal microbiota transplantation on clearance of carbapenem resistant enterobacteraceae
yong woon Shin, Incheon, Korea, Republic of

EP10.02
Gut microbiota depending on the atopic dermatitis severity in children in Eastern Siberia
Anna Barilo, Krasnoyarsk, Russian Federation

EP10.03
watercress and the gut
kyle stewart, newton abbot, devon, United Kingdom

 


Electronic Poster Round 11: Microbiota and intestinal disease

EP11.01
Trimebutine maleate as a multidimensional-antibacterial agent against functional dyspepsia: a prospective multicenter randomized, double-blind controlled trial
Jannis Kountouras, Thessaloniki, Greece

EP11.02
Gut microbiota disorders in patients with inflammatory bowel diseases
Natalia Baryshnikova, St-Petersburg, Russian Federation

EP11.03
Comparison of glucose and lactulose breath test results for detecting small intestinal bacterial overgrowth
Arta DENINA, Riga, Latvia

 

EP11.04
THE PREVALENCE OF HELICOBACTER PYLORI AND PROTOZOAN INVASIONS AND THE IMPACT ON THE PERFORMANCE OF ENZYMATIC DIGESTION
Guzel Isaeva, Kazan, Russian Federation

EP11.05
Fecal Microbiota Transplantation as treatment for recurrent Clostridiodes difficile infection in patients with Inflammatory Bowel Disease: Experiences of the Netherlands Donor Feces Bank
Emilie van Lingen, Leiden, Netherlands

EP11.06
A CONSIDERABLE RATE OF COVID-19 GI SYMPTOMS IS ASSOCIATED WITH ANTIMICROBIAL THERAPY: FINDINGS FROM A LARGE WESTERN PROSPECTIVE COHORT
Serena Porcari, Rome, Italy

 


Electronic Poster Round 12: Microbiota and cancer

EP12.01
The clinical outcomes of treatment for low grade gastric mucosa associated lymphoid tissue lymphoma unresponsive to Helicobacter pylori eradication
Sunah Suk, Seoul, Korea, Republic of

 


Electronic Poster Round 13: Gut microbiota manipulation

EP13.01
Initial experience of the first Brazilian stool bank with fecal microbiota transplantation for recurrent Clostridioides difficile infection
Luiz Gonzaga Coelho, BELO HORIZONTE, Brazil

EP13.02
Impact of high fat diets with different content of unsaturated fatty acids on hydrogen gas generation by the gut microbiota in rats
Anastasiia Ivanova, Moscow, Russian Federation

 


Electronic Poster Round 14: Microbiota detection and analyses

EP14.01
Circulating blood microbiome signatures in patients with liver cirrhosis: association between clinical parameters, circulating taxa and inflammatory cytokines
Rolandas Gedgaudas, Kaunas, Lithuania

EP14.02
Laboratory assessment of a device prototype for Methane and Hydrogen breath testing
Elena Kolomina, St. Petersburg, Russian Federation

EP14.03
Multiparameter flow cytometric enumeration of the commercial probiotic products
Katarzyna Sielatycka, Szczecin, Poland

EP14.04
In-depth comparison of different platforms for high throughput sequencing microbiome analyses of gastric mucosa
Alexander Link, Magdeburg, Germany

 

EHMSG 2020

European Helicobacter and Microbiota Study Group

© 2020 EHMSG

Core Agency

WMA GmbH

Alser Strasse 4, 1090 Vienna, Austria

  • zwitschern